LIVE WEBINAR
In-silico target discovery with the ConvergeCELL™ patient foundation model.
Join Iddo Weiner, PhD, Co-founder & CSO of Converge Bio, for a live look at ConvergeCELL, a patient-level foundation model trained on 46.5M cells across 9,843 patients, 927 studies, and 400+ diseases. See how in-silico perturbation turns single-cell and bulk RNA-seq into cell-type-resolved target and biomarker hypotheses, validated on held-out lupus, myeloma, and sepsis cohorts.
Wednesday, August 26, 2026
2:00 PM EDT · 9:00 PM IDT
DAYS
HOURS
MINUTES
SECONDS
WHAT YOU’LL LEARN
A technical session for computational biologists and translational R&D teams, followed by live Q&A.
YOUR PRESENTER
Iddo Weiner, PhD
Co-founder & CSO, Converge Bio
Leads the research behind Converge Bio’s foundation models for the life sciences, from antibody design to patient-level cell-state simulation.
01
A patient-level foundation model, not a cell-level one
Entire patient samples live in one embedding space, trained on 46.5M cells across 9,843 patients, 927 studies and 400+ diseases.
02
In-silico perturbation
Simulate gene and drug perturbations to generate mechanism-of-action hypotheses, and anticipate drug response and resistance before wet-lab work.
03
End-to-end discovery
From raw single-cell or bulk RNA-seq to cell-type-specific gene attribution, in one pass.
04
Results on held-out cohorts
Validated on lupus, multiple myeloma and sepsis, matching or beating differential-expression, ML and PaSCient foundation-model baselines.
05
The model release
What’s shipping, which modalities are supported, and how to run it on your own cohorts.
THE MODEL BEHIND THE SESSION
ConvergeCELL™ is trained on the largest patient-level single-cell corpus assembled to date.
46.5M
Cells
9,843
Patients
927
Studies
400+
Diseases